Dylann Cohn-Emery | Authors

September 28, 2022

Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.

September 12, 2022

Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.

September 11, 2022

At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.

August 27, 2022

Updated analysis results of from the IKEMA showed improvement in the depth of response to isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma.

June 07, 2022

In patients enrolled in the phase 1b portion of the KRYSTAL-1 trial who received adagrasib, the intracranial objective response rate was 32%.

June 06, 2022

Three-year follow-up of the CheckMate 9LA trial shows continued survival benefit to nivolumab/ipilimumab plus 2 cycles of chemotherapy in patients with metastatic non–small cell lung cancer.